Skip to nav Skip to content

Clinical Trial Search

294 Clinical Trials Found

Clinical Trial 21749

Phase 1/2, Open-Label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic Solid Tumor Malignancies
Disease Site: Cervix, Other Female Genital
PI: Avila, Monica

Clinical Trial 23399

A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases
Disease Site: Brain and Nervous System, Brain metastasis
PI: Yu, Hsiang-Hsuan (Michael)

Clinical Trial 23059

A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome
Disease Site: Myeloid and Monocytic Leukemia
PI: Sallman, David

Clinical Trial 22595

Disease Site: Multiple Myeloma
PI: Paba Prada, Claudia

Clinical Trial 21892

A Phase 2, Single-Arm, Open-Label Study using Itacitinib and Tafasitamab as Pre-Modulation in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Receiving CAR-T-Cell Therapy
Disease Site: Non-Hodgkin's Lymphoma
PI: Jain, Michael

Clinical Trial 22286

Disease Site: Leukemia, other
PI: Shah, Bijal

Clinical Trial 22557

Disease Site: Non-Hodgkin's Lymphoma
PI: Jain, Michael

Clinical Trial 23161

Immunologic Targeting of Native and Mutated ESR1 Receptor for Treatment of Hormone Receptor Expressing Metastatic Breast Cancer
Disease Site: Breast
PI: Soyano Muller, Aixa

Clinical Trial 20831

A Phase 1b/3 Double-Blind, Randomized,Active-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination with Lenalidomide Plus Rituximab in Subjects with Relapsed/Refractory Follicular Lymphoma
Disease Site: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
PI: Gaballa, Sameh

Clinical Trial 21024

A Phase IIa Study of Dendritic Cell Vaccines against HER2/HER3 and Pembrolizumab in Patients with Asymptomatic Brain Metastasis from Triple Negative Breast Cancer (TNBC) or HER2+ Breast Cancer (HER2+BC)
Disease Site: Brain and Nervous System
PI: Forsyth, Peter

Clinical Trial 20386

Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC
Disease Site: Lung
PI: Gray, Jhanelle

Clinical Trial 20339

Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma
Disease Site: Bones and Joints, Rhabdomyosarcoma
PI: Metts, Jonathan